2017-05-03 15:35:44 UTC

DDW® Symposium Will Focus on Biosimilars

May 3, 2017

AGA and the Crohn’s and Colitis Foundation will co-host a DDW Symposium on Biosimilars on Tuesday, May 9, from 2 to 3:30 p.m.

Join AGA and the Crohn’s and Colitis Foundation for a symposium at Digestive Disease Week® (DDW) 2017 to discuss biosimilars in GI practice. This symposium, Advent of Biosimilar Products in US GI Practice, will feature expert presentations from M. Stacey Ricci, MEng, ScD, of the U.S. Food and Drug Administration and AGA members Gary R. Lichtenstein, MD, AGAF; Brian G. Feagan, MD; and David T. Rubin, MD, AGAF.

Participants will learn about the U.S. regulatory pathway for approval of biosimilars. Experts will provide an overview of the evidence currently available on biosimilars for treatment of gastrointestinal disorders, with a focus on IBD. Approaches to educating and discussing the topic of biosimilars with patients will also be explored. At the end of the session, attendees will have the opportunity to ask questions during a Q&A discussion.

This program is supported by independent educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Pfizer Inc. The symposium is the first piece in an educational collaboration between AGA and the Crohn’s and Colitis Foundation, providing physician education programs on biosimilars.

To learn more about this symposium and other events at DDW, visit the DDW website.

More on Biosimilars

Principles of GI for the NP and PA

Aug. 10, 2018

Hear from the experts as they provide you with critical updates on treating and managing patients with a variety of GI disorders.

Talking With Your IBD Patients About Biosimilars

Dec. 20, 2017

In this on-demand video series, Sophie Balzora, MD, will provide an overview of the concerns patients may have about biosimilar therapies, and how best to address those concerns.

Insurance Barriers Should Not Hinder Step Therapy Treatment for IBD

Dec. 13, 2017

AGA participated in a congressional briefing to highlight the need for physician use of step therapy treatment without barriers.